Michigan State University's Dr. Norbert Kaminski Begins Pre-Clinical Study of GB Sciences' Neuroprotective Cannabis Compounds For Parkinson's Disease

LAS VEGAS, Aug. 6, 2018 /PRNewswire/ -- GB Sciences, Inc. (OTCQB: GBLX) has signed an agreement to initiate research collaborations with Dr. Norbert Kaminski, Professor of Pharmacology & Toxicology at Michigan State University. Dr. Kaminski will study the toxicology, anti-inflammatory properties, and immunomodulatory activity of GB Sciences' proprietary cannabis-based neuroprotective compounds using a diverse array of assays employing human primary white blood cells. Mounting evidence suggests that the inflammatory processes in the brain contribute to the pathologies of Parkinson's, Alzheimer's and HIV-Associated Neurocognitive Disorders. The human primary blood cell screens performed at MSU are state-of-the-science models for evaluating the effects of compounds on the human immune system and allow MSU researchers to assess both the toxicity and anti-inflammatory potential of GB Sciences' neuroprotective compounds, including their Parkinson's formulations and others.

"GB Sciences is honored to be working with Dr. Kaminski on this project. He pioneered studies of the effects of cannabis on the immune system," explains Dr. Andrea Small-Howard, Chief Science Officer of GB Sciences. "More recently, Dr, Kaminski's work has centered around the immune modulating effects of cannabis consumption on HIV/AIDS patients. In 2017, he demonstrated a relationship between cannabis use and improved brain health in HIV/AIDS patients who used cannabis versus those who did not. Dr. Kaminski has further theorized that cannabis use by HIV/AIDS patients may reduce their risk of HIV-Associated Neurocognitive Disorder (HAND) by reducing levels of inflammatory white blood cells in their brains. This same neuroinflammation may be a major contributing factor in a number of related neurological disorders such as Parkinson's disease and Alzheimer's disease."

GB Sciences holds a formidable Intellectual Properties portfolio and has engaged the cooperation of top research Universities and CRO's to maximize its potential. Given the breadth and depth of the disease states covered by the portfolio, the Company has adopted a 'Best of Breed' approach to identify, engage, and develop the most effective team to research and create the needed formulations on a project by project basis.

"GB Sciences is very fortunate to be working with Dr. Kaminski on this important research and development project on our lead therapeutic compounds," said John Poss, CEO and Chairman of GB Sciences, Inc. "Our company is committed to working with top universities and CRO's to achieve our goal of helping to unlock the therapeutic potential of cannabis."

MSU has begun testing GB Sciences' neuroprotective compounds at their Institute for Integrative Toxicology, where Dr. Kaminski serves as Director.

About GB Sciences, Inc.

GB Sciences, Inc. (OTCQB: GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. The Company's goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. To learn more about GB Sciences, Inc., go to: http://gbsciences.com.

Forward-Looking Statements

This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

Note: Although the Company's research and development activities are not illegal, the production and sale of cannabis products violate federal laws as they presently exist.

Contact Information

GB Sciences, Inc., 3550 West Teco Ave., Las Vegas, NV 89118
866-721-0297, or
Tom Arcuragi, EVP, tom@gbsciences.com

View original content with multimedia:http://www.prnewswire.com/news-releases/michigan-state-universitys-dr-norbert-kaminski-begins-pre-clinical-study-of-gb-sciences-neuroprotective-cannabis-compounds-for-parkinsons-disease-300692139.html

SOURCE GB Sciences, Inc.


Back to news